EVMN NYSE Week ended 31 Jul 2026

Weekly Investor Report

Evommune, Inc. · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 11.25 USD
-1.0% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -47.0% below the Trend Line and sits at 3.4% of its 52-week range. The latest completed week returned -1.0%, after a -13.2% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 57/100 conviction, while the latest news-sentiment score is 47/100. Near-term considerations: volume confirmation is below normal; earnings are due in 4d.

Setup score 26 out of 100
Latest Close 11.25 USD 31 Jul 2026
1W Return -1.0% latest completed week
4W Return -13.2% short-term follow-through
12W Return -50.9% quarterly tape
Trend Breadth 2.6% 1 of 39 weeks active
Volume Ratio 0.6x vs 13-week average
What is working
  • Next-week expectancy is positive at 57.26% based on similar historical setup states.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -1.0% Latest completed week; four-week move -13.2%. Indicator stack 1/17 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Positive 57.26% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Volatility 57/100 conviction; expected move 27.6%. News sentiment 47/100 27 relevant articles in the latest sentiment read. Event risk 4d Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -47.0% below the Trend Line and sits at 3.4% of its 52-week range. The latest completed week returned -1.0%, after a -13.2% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.6x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.1712-week average 0.28

12-week confirmation

Trend active1/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.17Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -13.2% over four weeks, -50.9% over 12 weeks, and - over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-1.0%
4W-13.2%
12W-50.9%
26W-37.8%
52W-
Active trend streak0 weeks
Active weeks in one year1
Trend breadth2.6%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-1.35Latest activity-pressure read.
Pressure change-103.7%Four-week change in activity pressure.
Leadership-Latest relative-leadership reading.
RS change-Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 73% Model confidence 70%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength77/100Blend of value, momentum, and quality. Underlying universe rank 24; rank 1 is best.
Value63/100Relative valuation strength. Underlying universe rank 38; rank 1 is best.
Quality62/100Profitability and accounting quality. Underlying universe rank 39; rank 1 is best.
Momentum63/100Medium-term price momentum. Underlying universe rank 38; rank 1 is best.
Growth63/100Revenue and earnings growth. Underlying universe rank 38; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
31.5x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-21.5%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
68.8%
Gross profit retained from each unit of revenue.
Operating margin
-584.5%
Operating profit retained from revenue.
Free-cash-flow margin
-613.3%
Free cash flow generated from revenue.
Return on invested capital
-21.5%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
4/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-15.9%
Net share repurchases relative to market value.
Shareholder yield
-15.9%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.5x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

EVMN shows volatility options pressure with a 57/100 conviction score, put-call volume ratio of 13.67, expected move of 27.6%, and Sharemaestro trend signal inactive.

Conviction57/100
Expected move27.6%
Put/call volume13.67
Pressure-75
Speculation42
Volatility96
Trend agreement25
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment47/100

Weighted news tone is neutral across 27 relevant articles.

7 positive · 14 neutral · 6 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings4dNext report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
Options expected move27.6%Nearest-chain priced movement where available.
52-week drawdown-66.1%Distance below the 52-week high.
13-week volatility14.8%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher10 of 2615 weeks finished lower.
Best week+82.4%Week of 13 Feb.
Worst week-48.5%Week of 3 Jul.
Latest week-1.0%Week of 31 Jul.

Shape of recent returns

Strong gains7
Modest gains3
Flat weeks1
Modest losses4
Sharp losses11
Recent vol14.8%13-week weekly-return volatility.
Base vol17.7%52-week weekly-return volatility.
Up/down split17/20Count of positive and negative weeks in the 52-week window.
Average skew11.2% / -9.3%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape29/100

Trend, activity pressure, participation, and risk combine to a 29/100 tape read.

 Indicator analysis14/100

Latest 12-week confirmation: trend 1/12, activity pressure 0/12, relative leadership 0/12.

Activity pressure 0.17; No reversal markers Next-Week ExpectancyPositive 57.26%

Next-week expectancy is positive with a 57.26% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors66/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 89; Small Cap Core rank 45 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options44/100

EVMN shows volatility options pressure with a 57/100 conviction score, put-call volume ratio of 13.67, expected move of 27.6%, and Sharemaestro trend signal inactive.

Volatility · Volatility expansion watch · Expected move 27.6% Sentiment47/100

Weighted news tone is neutral across 27 relevant articles.

Perceptive Advisors LLC Buys Shares of 448,350 Evommune, Inc. $EVMN Insiders50/100

No recent insider transaction evidence is stored.

 Earnings4d

Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202611.25 USD-1.0%21.23 USD20.66 USD-1.35-2.1MOff
24 Jul 202611.36 USD-6.4%21.43 USD20.90 USD-1.26-2.7MOff
17 Jul 202612.14 USD-8.1%21.62 USD21.16 USD-0.92-3.4MOff
10 Jul 202613.21 USD1.9%21.83 USD21.41 USD-0.71-6.1MOff
3 Jul 202612.96 USD-48.5%21.99 USD21.65 USD-0.66-15.3MOff
26 Jun 202625.18 USD17.9%22.29 USD21.90 USD-0.66-4.2MOff
19 Jun 202621.36 USD7.7%22.14 USD21.80 USD-0.83-2.1MOff
12 Jun 202619.83 USD-0.5%22.05 USD21.82 USD-0.84-2.6MOff
5 Jun 202619.92 USD-14.2%22.00 USD21.88 USD-0.65-2.0MOff
29 May 202623.23 USD1.6%21.95 USD21.95 USD-0.48-1.6MOn
22 May 202622.87 USD-0.2%-21.90 USD-0.30-2.2MOff
15 May 202622.92 USD0.0%-21.87 USD--2.1MOff
8 May 202622.92 USD-6.4%-21.83 USD--2.4MOff
1 May 202624.50 USD-3.5%-21.79 USD--1.4MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.